US expands scope of Trelegy Ellipta to include asthma
Trelegy Ellipta is now the first once-daily single inhaler triple therapy for the treatment of both asthma and COPD in the US
Read More
Tag: fluticasone furoate/umeclidinium/vilanterol
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
